Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Zimmer Biomet Holdings    ZBH

ZIMMER BIOMET HOLDINGS

(ZBH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Zimmer Holdings, Inc. : Zimmer Knee Component Shows New Type Of Failure

share with twitter share with LinkedIn share with facebook
02/06/2012 | 02:15pm EDT
   By Anjali Athavaley 
   Of  
 

A small percentage of patients who received replacement knee surgeries using a type of component made by Zimmer Holdings Corp. (ZMH) experienced an unexpected problem that can lead to the destruction of the implant, according to the abstract of a single-center study to be presented at a medical meeting this week.

The study, conducted by researchers at the Mayo Clinic in Rochester, Minn., is scheduled to be presented Thursday at a meeting of the American Academy of Orthopaedic Surgeons. Researchers looked at 1,373 total knee replacements performed at the center between 2000 and 2011 using a Zimmer NexGen knee with a specific type of tibial component. According to the abstract, 3.9% of the knees failed for various reasons.

A problem where the implant becomes loose from the surrounding bone accounted for 50% of total failures. More than 80% of the failures associated with that problem occurred because of isolated debonding, where the implant comes loose from cement.

Isolated debonding has not been seen before with other implants used at the center. It is unclear how widespread the problem is.

"We have spoken to high-volume users of the system, and they haven't reported any similar events," said Garry Clark, a Zimmer spokesman. He said the component in question represents 1.2% of Zimmer's tibial sales.

Tao Levy, an analyst at Collins Stewart, said in a note that while the specific component doesn't generate a material amount of revenue for Zimmer, "we believe a greater understanding of the factors surrounding the unexpected failure mechanism ... is important in determining whether this is an irrelevant study or something more significant that may impact other components."

Zimmer shares fell a fraction in recent trading to $62.17. The stock is up 16.4% this year.

-By Anjali Athavaley, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
THE LEAD CO., INC. 2.56% 361 End-of-day quote.-7.44%
ZIMMER BIOMET HOLDINGS 4.80% 139.38 Delayed Quote.-6.88%
share with twitter share with LinkedIn share with facebook
Latest news on ZIMMER BIOMET HOLDINGS
08/06NEUROONE MEDICAL TECHNOLOGIES : Announces Distribution Deal With Zimmer Biomet F..
AQ
08/05ZIMMER BIOMET : Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04ZIMMER BIOMET : Swings to 2Q Loss Amid Elective-Surgery Decline
DJ
08/04ZIMMER BIOMET HOLDINGS, INC. : Results of Operations and Financial Condition (fo..
AQ
08/04ZIMMER : 2Q Earnings Snapshot
AQ
07/30ZIMMER BIOMET HOLDINGS : half-yearly earnings release
07/24ACELRX PHARMACEUTICALS : Announces Exclusive Distribution and Promotion Partners..
AQ
07/06ZIMMER BIOMET : Notice of Proposed Class Action and Proposed Settlement Involvin..
PR
07/02ZIMMER BIOMET HOLDINGS, INC. : Change in Directors or Principal Officers, Regula..
AQ
06/29ZIMMER BIOMET : Announces Webcast and Conference Call of Second Quarter 2020 Fin..
PR
More news
Financials (USD)
Sales 2020 6 818 M - -
Net income 2020 -435 M - -
Net Debt 2020 6 995 M - -
P/E ratio 2020 -67,8x
Yield 2020 0,71%
Capitalization 28 859 M 28 859 M -
EV / Sales 2020 5,26x
EV / Sales 2021 4,28x
Nbr of Employees 19 900
Free-Float 66,5%
Chart ZIMMER BIOMET HOLDINGS
Duration : Period :
Zimmer Biomet Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIMMER BIOMET HOLDINGS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 146,50 $
Last Close Price 139,38 $
Spread / Highest target 25,6%
Spread / Average Target 5,11%
Spread / Lowest Target -29,0%
EPS Revisions
Managers
NameTitle
Bryan C. Hanson President, Chief Executive Officer & Director
Larry C. Glasscock Non-Executive Chairman
Kenneth R. Tripp Senior VP-Global Operations & Logistics
Suketu P. Upadhyay Executive VP, Chief Financial & Accounting Officer
David J. Kunz VP-Global Quality, Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
ZIMMER BIOMET HOLDINGS-6.88%28 859
ABBOTT LABORATORIES16.54%179 231
MEDTRONIC PLC-11.81%134 197
BECTON, DICKINSON AND COMPANY-5.72%74 325
DEXCOM, INC.101.47%42 194
BAXTER INTERNATIONAL INC.-3.46%40 868